WorldHeart is a developer of mechanical circulatory support systems. The Company is headquartered in Oakland, California, USA with additional facilities in Salt Lake City, Utah and Herkenbosch, Netherlands. WorldHeart's registered office is Ottawa, Ontario, Canada.
WorldHeart's transfer agent and registrar:
CIBC Mellon Trust Company
320 Bay Street, 7th Floor
M5H 4A6 Canada
Tel: (416) 643-5553
The number of common shares outstanding as of May 14, 2008 was 11,507,275 and 0 shares of preffered stock.
May 27, 2008
WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
May 15, 2008
Q-10 Quarterly Results
May 15, 2008
May 8, 2008
Triggering Events that Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Departure of Directors, and Other Events
This is WorldHeart
"World Heart Corporation is a worldwide pioneer and technology leader in heart assist therapy for end stage congestive heart failure. WorldHeart develops, manufactures and markets implantable heart assist devices that deliver pulsatile and rotary blood flow for temporary and long-term support to patients around the globe.
More than 1,700 patients with life-threatening heart failure have been supported by our leading Novacor® LVAS. As both temporary (Bridge-to-Transplant) and long-term support, the Novacor® LVAS increases our recipient's chance of survival and enables them to return to their families, homes, and hobbies.
WorldHeart's Novacor® LVAS is an implanted, wearable system that provides pulsatile circulatory support for patients with life-threatening heart failure. Novacor® LVAS has been implanted in more than 1,700 patients, and is the first mechanical circulatory support device to support a single patient for more than six years.
Novacor II LVAS
The Novacor II LVAS, currently under development, is a next-generation implanted, wearable system that provides pulsatile circulatory support for patients with life-threatening heart failure. The Novacor II LVAS is smaller in size than the original Novacor® LVAS. The system has a unique design that offers many advantages over currently available pulsatile VADs, including:
* Smaller size
* Simpler, quieter operation
* Reliable and durable, with no bearings or wearing elements
* Can be fully implantable without a volume compensator
* Use as LVAD or RVAD
The Levacor VAD is an advanced, next-generation rotary blood pump intended for Destination Therapy. Unlike the initial generation of rotary pumps with blood-lubricated bearings, the Levacor VAD is a compact, centrifugal pump with an impeller that is completely magnetically levitated (MagLev™). Full magnetic levitation eliminates wear mechanisms within the pump. It also permits greater clearances and more optimized blood flow around the impeller while eliminating dependence on the patient's blood for suspension. The Levacor VAD's levitation technology employs a unique combination of passive and single-axis active control, resulting in a system of optimal simplicity." worldheart.com